In response to a furor over medicines discovered with taxpayer dollars, Sen. Bernie Sanders (I-Vt.) is proposing a new rule to require drug makers to charge fair prices.

The move would force federal agencies and federally funded nonprofit institutions, including universities, to negotiate a reasonable pricing agreement before granting exclusive rights to make prescription drugs.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Senator has a good idea but BIG PHARMA who have had taste of blood (profits) is not going to give in easily. They could easily refuse to bring drugs to the market. If that happens, Generics should be given the right to go forward and commercialize such drugs.

    • There are a number of markets that would actually make sense to pull out of if we don’t get our price, and when that happens this “fair pricing concept” goes away. For example, Canada is such a small market that it costs more to hassle with Health Canada then it is worth. And when you have the market leader they stand up and listen. For example in the 1990’s Synthroid was the market leader and we were getting 30 cent’s a pill in the US vs 3 cents a pill for the inferior quality LT4’s. When we didn’t get our price over the border we internally discussed pulling the product from Canadian shelves, leaving 800,000 Canadian hypothroids without a real alternative. You are right, pharma is like the Great White. When the blood is in the water the PharmaSharks get their way.

      Maybe Jane Sanders get fair pricing on the fine she pays for bilking the sate of Vt.

Your daily dose of news in health and medicine

Privacy Policy